

Viral Hepatitis Case Presentation Request

Please send requests to: Shayna.Jefferson-Williams@dph.ga.gov



Encounter Date:	/ Site: Clinician:				
ECHO ID (GDPH Us	e Only):				
Type of Patient:	□ Now action □ □ Follow up nation				
Age:	☐ New patient ☐ Follow-up patient				
Gender:	☐ Male ☐ Female ☐ Non-conforming Transgender: ☐ FTM ☐ MTF				
Genaer.					
Insurance:	□ Other □ Medicaid Plan:				
	☐ Medicare ☐ Commercial Health Insurance Plan:				
	□None				
Question(s) for E	СНО				
Community:					
Viral Henatitis / Liv	ver Disease History				
HCV infection	☐Yes Year of Diagnosis: ☐No				
HBV infection	☐Yes Year of Diagnosis: ☐No				
HCV GT/VL, HIV c	<u> </u>				
infection, NS5A	HBV DNA				
mutations	HIV co-infection: Yes No				
	Y93 mutation: □Yes □No				
Previous / Curren	nt HCV ☐ Treatment Naïve ☐ Treatment Experienced Past response:				
Treatment	Regimen: Duration:				
Fibrosis Staging	Stage 0-1 Stage 2 Stage 3 Stage 4 (OK to select more than one stage)				
	Assessment Tool(s):				
	☐FIB-4/APRI ☐FibroScan ☐FibroTEST (or similar) ☐Liver Biopsy ☐Imaging				
Cirrhosis	□ None □ Ascites □ Hepatic encephalopathy □ Variceal bleed				
Complications	☐ Compensated ☐ De-compensated				
Abdominal Imagi					
Hamata adli dan	Date:Impression:				
Hepatocellular Carcinoma (HCC)	☐Yes ☐No Year of Diagnosis: Treatment:				
carcinoma (nec)	Treatment:				
Physical Exam					
	ma/Spider angiomata Palpable Liver/Spleen Ascites Peripheral edema				
☐Hepatic Enceph					
	· · · · · · · · · · · · · · · · · · ·				
Medical History					
□HTN □Hyperlipidemia □DM □Cardiovascular Disease					
Other					
Davishiatuis History					
Psychiatric History					
☐ Depression ☐ Other	□ Anxiety □ Bipolar Disease □ Schizophrenia				



Viral Hepatitis Case Presentation Request

Please send requests to: Shayna.Jefferson-Williams@dph.ga.gov



Alcohol and Drug U	se				
☐Current ETOH		Current IVDU	□Curren	t Illicit Drug Use	
☐ History of heavy	ETOH	Past IVDU	□ Other _		
Current Medication	S				
Medication Name/Dose		Medication Name/Dose		Medication Name/Dose	
Body Mass Index (B	MI):				
(•		
Lab Results					
ALT		INR		anti-HAV	
AST		FibroTEST		HBsAg	
Alk phos		Fib-4*		anti-HBs	
Albumin		APRI*		anti-HBc	
Total bili		FibroScan kPa		HBV DNA	
Hgb		FibroScan IQR%		HBeAg	
Platelets		FibroScan CAP score		anti-HBe	
Creatinine					
Other Labs:					
Other 2003.					
If Cirrhotic, please i	ndicate Child-Pugh	and MELD-Na Scores:			
Child Pugh Score:	□A □B □C F	Points:			
MELD-Na Score*:		_			
FIB-4 Interpretation	•				
Points < 1.45: Cirrh					
	≤ 3.25 : Indetermina	te			
Points > 3.25: Cirrh					
	, , , , , , , , , , , , , , , , , , ,				
APRI Interpretation					
Points ≤ 0.5: Signif	icant Fibrosis or Cir	rhosis less likely			
		sis indeterminate, Cirrh	nosis less likely		
Points > 1 and ≤ 1.	5: Significant Fibros	sis more likely, Cirrhosi	s indeterminate		
	_	sis more likely but Cirrh	nosis indeterminate		
Points > 2: Significa	ant Fibrosis and Cir	rhosis more likely			

Child-Pugh Score for Cirrhosis Mortality

http://www.mdcalc.com/child-pugh-score-forcirrhosis-mortality/ *For Clinical Calculators (APRI, MELD, etc.), visit:

http://www.hepatitisc.uw.edu/page/clinical-calculators/meld